Shammaa Riam, El-Kadiry Abed El-Hakim, Abusarah Jamilah, Rafei Moutih
Canadian Centre for Regenerative Therapy, Toronto, ON, Canada.
IntelliStem Technologies Inc., Toronto, ON, Canada.
Front Cell Dev Biol. 2020 Feb 18;8:72. doi: 10.3389/fcell.2020.00072. eCollection 2020.
Mesenchymal stem cells (MSCs) are competent suitors of cellular therapy due to their therapeutic impact on tissue degeneration and immune-based pathologies. Additionally, their homing and immunomodulatory properties can be exploited in cancer malignancies to transport pharmacological entities, produce anti-neoplastic agents, or induce anti-tumor immunity. Herein, we create a portfolio for MSC properties, showcasing their distinct multiple therapeutic utilities and successes/challenges thereof in both animal studies and clinical trials. We further highlight the promising potential of MSCs not only in cancer management but also in instigating tumor-specific immunity - i.e., cancer vaccination. Finally, we reflect on the possible reasons impeding the clinical advancement of MSC-based cancer vaccines to assist in contriving novel methodologies from which a therapeutic milestone might emanate.
间充质干细胞（MSCs）因其对组织退化和免疫相关病症的治疗作用，成为细胞治疗的有力候选者。此外，它们的归巢和免疫调节特性可用于癌症治疗，以运输药理实体、产生抗肿瘤药物或诱导抗肿瘤免疫。在此，我们构建了一个关于MSCs特性的综述，展示了它们在动物研究和临床试验中独特的多种治疗用途及其成功与挑战。我们进一步强调了MSCs不仅在癌症治疗中，而且在激发肿瘤特异性免疫（即癌症疫苗接种）方面的巨大潜力。最后，我们思考了阻碍基于MSCs的癌症疫苗临床进展的可能原因，以助力设计可能带来治疗里程碑的新方法。
